Clinical trial Recruiting at 1 site Interventional Ages 18 to 90

Using muscle relaxants to improve electroporation ablation safety

Official title: The Use of Muscle Relaxants During Electroporation Ablation (PFA) as a Potential Protective Factor Against Damage to Transverse Striated Muscle Tissue and the Heart

Run by 4th Military Clinical Hospital with Polyclinic, Poland · NCT06707532 · Data updated 2026-11-12

This study tests if using muscle relaxants during a heart procedure called electroporation ablation can make it safer for patients and help them recover faster.

Quick facts

Study typeInterventional
Ages18 Years to 90 Years
SexAll
Enrollment32 (estimated)
Sponsor4th Military Clinical Hospital with Polyclinic, Poland
Academic / other
Locations1 site (Wroclaw, Lower Silesian Voivodeship)
StatusRecruiting
StartedAugust 1, 2024
Main results expectedDecember 1, 2025
Study endsDecember 1, 2025
Registry record updatedNovember 27, 2024
Trial IDNCT06707532 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients requiring PFA ablation for cardiac indications who can provide informed consent.

Probably not a fit

Patients with allergies to the anesthetics used or genetic neuromuscular diseases will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the use of muscle relaxants during electroporation ablation (PFA) to enhance patient safety by minimizing skeletal muscle damage and assessing myocardial damage. Patients will be randomized into two groups: one receiving general anesthesia without muscle relaxants and the other with rocuronium. The study aims to improve the quality of the PFA procedure and accelerate recovery times. A total of 32 patients will participate, with a double-blind design to ensure unbiased results.

Why it matters

Potential benefit: If successful, this approach could lead to safer and more effective electroporation ablation procedures for patients with cardiac conditions.

How similar studies have gone: While the use of muscle relaxants in similar procedures has been explored, this specific application in electroporation ablation is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with requirement for PFA ablation for cardiac indications and ability to provide informed consent for study participation

Exclusion Criteria:

* Patients with allergies to the general anaesthetics used, genetic diseases of the neuromuscular plateau - e.g. Duchenne dystrophy, myasthenia gravis - and patients who do not gived informed consent to participate in the study will be excluded from the study.

Where it's running

  • 4th Military Clinical Hospital with Polyclinic
    Wroclaw, Lower Silesian Voivodeship, Poland
    Recruiting

Study contacts

  • Principal investigator: Marek Szamborski, MD — Senior Assistant
  • Study coordinator: Marek Szamborski, MD
  • Email: mszamborski@4wsk.pl
  • Phone: 698-448-639

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.